NASDAQ:SLDB • US83422E2046
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SOLID BIOSCIENCES INC (SLDB).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-03-20 | Guggenheim | Initiate | Buy |
| 2026-03-20 | Needham | Reiterate | Buy -> Buy |
| 2026-03-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-03-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-03-11 | Wedbush | Reiterate | Outperform -> Outperform |
| 2026-02-09 | Needham | Reiterate | Buy -> Buy |
| 2026-01-14 | Needham | Reiterate | Buy -> Buy |
| 2025-12-04 | Needham | Initiate | Buy |
| 2025-11-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-05 | Citigroup | Maintains | Buy -> Buy |
| 2025-11-04 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-04 | Barclays | Maintains | Overweight -> Overweight |
| 2025-08-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-14 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-13 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-06-26 | Citigroup | Initiate | Buy |
| 2025-06-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-06 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-05-19 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-16 | Barclays | Maintains | Overweight -> Overweight |
| 2025-05-16 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-05-16 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-03-13 | JP Morgan | Maintains | Overweight -> Overweight |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 13.62M | 8.09M -40.60% | 897.6K -100.00% | 5.865M | 112.35M 1,815.60% | 278.79M 148.14% | 477.84M 71.40% | 702.24M 46.96% | 975.08M 38.85% | 1.225B 25.63% | |||||
| EBITDA YoY % growth | -82.55M 29.14% | -69.29M 16.06% | -92M -32.78% | -104.04M -10.58% | -118.83M -25.37% | -181.441M -42.26% | -224.499M -23.73% | -252.137M -12.31% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -86.47M 27.53% | -72.25M 16.45% | -94.41M -30.67% | -107.298M -10.49% | -126.633M -24.62% | -182.665M -40.51% | -212.197M -16.17% | -234.948M -10.72% | -161.714M 31.17% | -33.816M 79.09% | 88.027M 360.31% | 289.12M 228.44% | 486.05M 68.11% | 618.51M 27.25% | |
| Operating Margin | N/A | -530.47% | -1,167.00% | -11,953.86% | N/A | N/A | N/A | -4,005.93% | -143.94% | -12.13% | 18.42% | 41.17% | 49.85% | 50.49% | |
| EPS YoY % growth | -24.75 43.69% | -10.20 58.79% | -12.13 -18.92% | -4.82 60.43% | -3.00 36.67% | -2.14 29.56% | -2.08 3.00% | -1.99 4.14% | -1.19 40.26% | -0.13 89.02% | 0.83 739.06% | 1.84 120.54% | 3.13 70.07% | 4.13 32.01% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.53 47.08% | -0.52 12.07% | -0.52 -24.76% | -0.54 -12.88% | -0.49 6.52% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -49.538M -32.31% | -52.447M -32.29% | -56.271M -37.58% | -60.37M -28.75% | N/A |
| EBIT Q2Q % growth | -50.1M -25.58% | -48.728M -21.66% | -49.987M -19.89% | -51.89M -7.97% | -51.448M -2.69% |
All data in USD
19 analysts have analysed SLDB and the average price target is 16.04 USD. This implies a price increase of 140.15% is expected in the next year compared to the current price of 6.68.
SOLID BIOSCIENCES INC (SLDB) will report earnings on 2026-05-13.
The consensus EPS estimate for the next earnings of SOLID BIOSCIENCES INC (SLDB) is -0.53 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering SOLID BIOSCIENCES INC (SLDB) is 19.